Loading clinical trials...
Loading clinical trials...
A Phase 1b, In-Patient Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of the Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
Conditions
Interventions
Roluperidone 64 mg
Olanzapine 10 MG
Locations
3
United States
Collaborative Neuroscience Research, LLC
Garden Grove, California, United States
CBH Health, LLC
Gaithersburg, Maryland, United States
Hassman Research Institute
Marlton, New Jersey, United States
Start Date
October 13, 2023
Primary Completion Date
January 12, 2024
Completion Date
January 12, 2024
Last Updated
March 26, 2025
NCT06907420
NCT06993831
NCT06067984
NCT05582980
NCT06653829
NCT05764148
Lead Sponsor
Minerva Neurosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions